- Home
- NVRI vs RGNX Comparison
NVRI vs RGNX Comparison
Compare NVRI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- RGNX
- Stock Information
- Founded
- NVRI 1853
- RGNX 2008
- Country
- NVRI United States
- RGNX United States
- Employees
- NVRI 13000
- RGNX N/A
- Industry
- NVRI Diversified Commercial Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVRI Miscellaneous
- RGNX Health Care
- Exchange
- NVRI Nasdaq
- RGNX Nasdaq
- Market Cap
- NVRI 572.2M
- RGNX 459.1M
- IPO Year
- NVRI N/A
- RGNX 2015
- Fundamental
- Price
- NVRI $7.14
- RGNX $9.18
- Analyst Decision
- NVRI Hold
- RGNX Strong Buy
- Analyst Count
- NVRI 1
- RGNX 12
- Target Price
- NVRI $10.00
- RGNX $36.36
- AVG Volume (30 Days)
- NVRI 661.4K
- RGNX 886.8K
- Earning Date
- NVRI 10-31-2024
- RGNX 11-06-2024
- Dividend Yield
- NVRI N/A
- RGNX N/A
- EPS Growth
- NVRI N/A
- RGNX N/A
- EPS
- NVRI N/A
- RGNX N/A
- Revenue
- NVRI $2,086,473,000.00
- RGNX $84,327,000.00
- Revenue This Year
- NVRI $16.52
- RGNX $7.91
- Revenue Next Year
- NVRI $0.21
- RGNX $214.75
- P/E Ratio
- NVRI N/A
- RGNX N/A
- Revenue Growth
- NVRI N/A
- RGNX N/A
- 52 Week Low
- NVRI $5.65
- RGNX $8.54
- 52 Week High
- NVRI $12.79
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- NVRI 35.57
- RGNX 43.02
- Support Level
- NVRI $6.57
- RGNX $8.87
- Resistance Level
- NVRI $7.57
- RGNX $12.11
- Average True Range (ATR)
- NVRI 0.39
- RGNX 0.96
- MACD
- NVRI 0.05
- RGNX -0.05
- Stochastic Oscillator
- NVRI 44.53
- RGNX 17.17
About NVRI Enviri Corporation
Enviri Corp engages in providing a broad range of environmental services and related solutions. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their complex environmental challenges.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.